After Reaching Milestone, Is PROVECTUS BIOPHARMACEUTICALS INC (OTCMKTS:PVCT)’s Short Interest Revealing Something?

May 14, 2018 - By Richard Conner

Investors sentiment increased to Infinity in 2017 Q4. Its up Infinity, from 0.33 in 2017Q3. It increased, as 0 investors sold Provectus Biopharmaceuticals, Inc. shares while 0 reduced holdings. 2 funds opened positions while 0 raised stakes. 138,500 shares or 592.50% more from 20,000 shares in 2017Q3 were reported.
Academy Cap Mngmt Tx has invested 0% in Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT). Budros Ruhlin & Roe holds 40,000 shares. Focused Wealth Management Incorporated has 0% invested in Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) for 9,250 shares.

The stock of PROVECTUS BIOPHARMACEUTICALS INC (OTCMKTS:PVCT) registered a decrease of 51.12% in short interest. PVCT’s total short interest was 834,800 shares in May as published by FINRA. Its down 51.12% from 1.71 million shares, reported previously. With 2.11M shares average volume, it will take short sellers 0 days to cover their PVCT’s short positions. The short interest to PROVECTUS BIOPHARMACEUTICALS INC’s float is 0.25%.

The stock increased 3.93% or $0.00295 during the last trading session, reaching $0.07805. About 31,068 shares traded. Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) has 0.00% since May 14, 2017 and is . It has underperformed by 11.55% the S&P500.

Provectus Biopharmaceuticals, Inc., a biopharmaceutical company, engages in developing ethical pharmaceuticals for oncology and dermatology indications. The company has market cap of $29.71 million. The Company’s prescription drug candidates includes PV-10, which is in Phase III study for cutaneous melanoma; completed Phase II study for metastatic melanoma; completed Phase I study for liver and breast cancers; and phase 1b/2 study for pembrolizumab. It currently has negative earnings. The firm is also developing PH-10 that has completed Phase II randomized study for the treatment of psoriasis and atopic dermatitis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.